You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 62 No. 7, July 2005 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Contribution
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (26)
 •Contact me when this article is cited
 Related Content
 •Related article
 •Similar articles in this journal
 Topic Collections
 •Pediatric Neurology
 •Radiologic Imaging
 •Magnetic Resonance Imaging
 •Alert me on articles by topic

Follow-up of 89 Asymptomatic Patients With Adrenoleukodystrophy Treated With Lorenzo’s Oil

Hugo W. Moser, MD; Gerald V. Raymond, MD; Shou-En Lu, PhD; Larry R. Muenz, PhD; Ann B. Moser, BA; Jiahong Xu, MS; Richard O. Jones, PhD; Daniel J. Loes, MD; Elias R. Melhem, MD; Prachi Dubey, MD, MPH; Lena Bezman, MD, MPH; N. Hong Brereton, MS, RD; Augusto Odone

Arch Neurol. 2005;62:1073-1080.

Objectives  To identify asymptomatic boys with X-linked adrenoleukodystrophy who have a normal magnetic resonance image (MRI), and to assess the effect of 4:1 glyceryl trioleate–glyceryl trierucate (Lorenzo’s oil) on disease progression.

Method  Eighty-nine boys (mean ± SD baseline age, 4.7 ± 4.1 years; range, 0.2-15 years) were identified by a plasma very long-chain fatty acids assay used to screen at-risk boys. All were treated with Lorenzo’s oil and moderate fat restriction. Plasma fatty acids and clinical status were followed for 6.9 ± 2.7 years. Changes in plasma hexacosanoic acid levels were assessed by measuring the length-adjusted area under the curve, and a proportional hazards model was used to evaluate association with the development of abnormal MRI results and neurological abnormalities.

Results  Of the 89 boys, 24% developed MRI abnormalities and 11% developed both neurological and MRI abnormalities. Abnormalities occurred only in the 64 patients who were aged 7 years or younger at the time therapy was started. There was significant association between the development of MRI abnormalities and a plasma hexacosanoic acid increase. (For a 0.1-µg/mL increase in the length-adjusted area under the curve for the hexacosanoic acid level, the hazard ratio for incident MRI abnormalities in the whole group was 1.36; P = .01; 95% confidence interval, 1.07-1.72.) Results for patients aged 7 years or younger were similar (P = .04).

Conclusions  In this single-arm study, hexacosanoic acid reduction by Lorenzo’s oil was associated with reduced risk of developing MRI abnormalities. We recommend Lorenzo’s oil therapy in asymptomatic boys with X-linked adrenoleukodystophy who have normal brain MRI results.


Author Affiliations: Kennedy Krieger Institute and Departments of Neurology and Pediatrics, Johns Hopkins University, Baltimore, Md (Drs H. W. Moser, Raymond, A. B. Moser, Jones, Dubey, and Bezman); Division of Biometrics, University of Medicine and Dentistry of New Jersey, Piscataway (Dr Lu); Westat, Rockville, Md (Drs Muenz and Xu); Suburban Radiological Consultants Ltd, Minneapolis, Minn (Dr Loes); Department of Radiology, University of Pennsylvania, Philadelphia (Dr Melhem); General Clinical Research Center, Johns Hopkins School of Medicine, Baltimore (Dr Brereton); and Myelin Project, Dunn Loring, Va (Mr Odone).


RELATED ARTICLE

Lorenzo’s Oil: Advances in the Treatment of Neurometabolic Disorders
Raymond Ferri and Phillip F. Chance
Arch Neurol. 2005;62(7):1045-1046.
EXTRACT | FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Hugo W. Moser, MD (1924-2007)
Raymond
Arch Neurol 2007;64:758-759.
FULL TEXT  

Uptake and metabolism of plasma-derived erucic acid by rat brain
Golovko and Murphy
J. Lipid Res. 2006;47:1289-1297.
ABSTRACT | FULL TEXT  

Cognitive Evaluation of Neurologically Asymptomatic Boys With X-linked Adrenoleukodystrophy
Cox et al.
Arch Neurol 2006;63:69-73.
ABSTRACT | FULL TEXT  

Adrenoleukodystrophy: New Approaches to a Neurodegenerative Disease
Moser et al.
JAMA 2005;294:3131-3134.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2005 American Medical Association. All Rights Reserved.